Your browser doesn't support javascript.
loading
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.
Li, Xingzhi; Chen, Jie; Wang, Xiaobo; Bai, Tao; Lu, Shaolong; Wei, Tao; Tang, Zhihong; Huang, Chengwen; Zhang, Bin; Liu, Bowen; Li, Lequn; Wu, Feixiang.
Affiliation
  • Li X; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Chen J; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Wang X; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Bai T; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Lu S; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Wei T; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Tang Z; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Huang C; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Zhang B; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Liu B; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Li L; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Wu F; Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Front Oncol ; 13: 1110689, 2023.
Article in En | MEDLINE | ID: mdl-36793614

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2023 Type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2023 Type: Article Affiliation country: China